ArticleF&S reports2025
Oncological safety and fertility outcomes of controlled ovarian stimulation in patients with early-stage endometrial cancer.
Article in F&S reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the oncological safety and efficacy with regard to reproductive outcomes of controlled ovarian stimulation (OS) with levonorgestrel-releasing intrauterine system (LNG-IUS). Design: Retrospective cohort study. Subjects: Patients presenting with complex endometrial hyperplasia or early-stage endometrial carcinoma (EC), managed with levonorgestrel-releasing intrauterine system. Exposure: Controlled OS. Main Outcome Measures: The primary outcome of the present study was to evaluate the oncological safety of controlled OS on disease progression, and the secondary outcome was to explore fertility outcomes in patients treated with LNG-IUS. Time-to-event outcomes were visualized as Kaplan-Meier plots and hazard ratios (HRs) with 95% confidence intervals (CIs). Results: Thirty-four patients, with a median age of 34 years (interquartile range [IQR], 30-38) and body mass index of 29.6 kg/m Conclusion: There may be an oncologically safe window of opportunity for fertility preservation and conception for patients on LNG-IUS diagnosed with early-stage EC, wishing to complete their family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.